EUVIMED · CrossrefJournal
Journal of Hematology & Oncology
ISSN 1756-8722 · Springer Science and Business Media LLC
Latest articles
Chemotherapy-induced mast-cell degranulation constrains tertiary lymphoid maturation in lung cancer brain metastasis
Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease
Antibody–drug conjugates in HR-positive, HER2-negative metastatic breast cancer: evolving clinical roles and translational directions
Di/tripeptides in cancer: from mechanisms to therapeutics
Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study)
Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR
Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial
A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors
Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1
PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Plonmarlimab, a GM-CSF-neutralizing antibody, for macrophage activation syndrome
Global cancer statistics among older adults in 2024 with projections to 2050: a multi-source population-based analysis
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis
Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives
Glutathione reductase deficiency potentiates the immunogenicity of ferroptosis and cuproptosis via amplified reactive oxygen species accumulation and cGAS-STING pathway activation
High-definition spatial transcriptomics visualizes the cellular and molecular architecture underlying perineural invasion in localized prostate cancer
Current and future therapies for triple-negative breast cancer
Plasma biomarkers predicting development of lung cancer 5 years before diagnosis
Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies
The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026
A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment
Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities
Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting
EUVIMED